List of Excipients in Branded Drug ELCYS

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Exela Pharma Sciences LLC	ELCYS	cysteine hydrochloride	51754-1008	WATER	2039-01-15

Elcys Excipient Strategy and Commercial Opportunities

Last updated: August 16, 2026

Elcys is a preservative-free cysteine hydrochloride injection used as an additive to amino acid solutions in parenteral nutrition for neonatal and pediatric patients. Its commercial differentiation is driven less by a complex excipient system than by sterile manufacturing, low-endotoxin control, pH management, container compatibility, and pharmacy workflow. The product’s narrow formulation provides opportunities for suppliers of parenteral excipients, ready-to-use nutrition systems, specialty packaging, and admixture technologies.

What is Elcys and how is it used?

Elcys contains cysteine hydrochloride injection, USP, at a concentration of 50 mg/mL. It is added to amino acid solutions used in total parenteral nutrition, particularly when cysteine supplementation is needed for premature and full-term infants and other pediatric patients.

The product is administered intravenously only after dilution into an appropriate parenteral nutrition solution. It is not intended for direct intravenous administration. The FDA label identifies the product as preservative-free and packaged as a single-dose vial. The labeled inactive ingredients are hydrochloric acid and Water for Injection [1].

Attribute	Elcys
Active ingredient	Cysteine hydrochloride
Strength	50 mg/mL
Dosage form	Sterile injectable solution
Primary use	Additive to amino acid solutions in parenteral nutrition
Key patient segment	Neonatal and pediatric patients
Preservatives	None listed
Core excipients	Hydrochloric acid and Water for Injection
Administration	Diluted into parenteral nutrition solution
FDA application	NDA 209570
Sponsor	Exela Pharma Sciences
Primary commercial channel	Hospitals, neonatal intensive-care units, pediatric nutrition services, compounders

The product’s clinical value is linked to the role of cysteine in parenteral nutrition. Neonatal patients may have limited capacity to synthesize cysteine, and cysteine supplementation can support the sulfur amino acid requirements of patients receiving intravenous nutrition [1].

What excipients are used in Elcys?

Elcys uses a minimal excipient system consisting of Water for Injection and hydrochloric acid. Hydrochloric acid functions primarily as a pH-adjusting agent. Water for Injection is the aqueous vehicle.

The limited excipient composition reduces conventional formulation complexity but increases the importance of process controls. The formulation must maintain chemical stability, sterility, endotoxin limits, container closure integrity, and compatibility with amino acid solutions and other parenteral nutrition components.

Elcys excipient profile

Excipient	Functional role	Commercial relevance
Water for Injection	Vehicle	Requires validated pharmaceutical water generation, storage, distribution, and microbiological control
Hydrochloric acid	pH adjustment and acidification	Requires concentration control, low-metal specifications, and compatibility with the final container
No preservative	Supports neonatal and parenteral use	Increases reliance on aseptic processing and single-dose packaging
No surfactant listed	Avoids additional injectable excipient burden	Limits formulation latitude for solubility or interfacial stabilization

The formulation should be evaluated as an acidified amino-acid additive rather than as a conventional multidose injectable. The principal technical risk is not excipient count. It is the interaction among cysteine degradation, solution pH, oxygen exposure, trace metals, sterilization conditions, and the final container system.

How does pH affect Elcys formulation and stability?

pH is the most commercially important formulation variable in Elcys. Cysteine contains a reactive thiol group that can undergo oxidation to cystine and other degradation products. Acidic conditions can reduce some degradation pathways, but excessive acidity creates handling, compatibility, and admixture risks.

A commercial development program should establish:

• Cysteine assay and related-substance limits over shelf life.
• Cystine formation under normal and accelerated conditions.
• pH drift after storage and after dilution into amino acid solutions.
• Compatibility with dextrose, electrolytes, minerals, vitamins, and lipid emulsions used in parenteral nutrition.
• The effect of oxygen headspace and container permeability.
• The effect of trace metals, including iron and copper.
• In-use stability after vial entry and after admixture.
• Precipitation or visible-particle risk in the final nutrition solution.

Hydrochloric acid is a simple pH modifier, but its concentration and addition process can influence batch uniformity. Small pH differences may affect cysteine oxidation, solution appearance, and compatibility after transfer to the parenteral nutrition container.

What excipient opportunities exist for Elcys competitors?

The most credible commercial opportunities involve excipient quality, packaging, and administration rather than a new inactive-ingredient platform.

Low-endotoxin Water for Injection

A supplier that can provide high-volume, low-bioburden, low-endotoxin Water for Injection with strong supply continuity may capture value in cysteine injection manufacturing. The product is used in highly sensitive neonatal and pediatric settings, where endotoxin and particulate control are central quality attributes.

Opportunities include:

• Validated WFI systems for sterile injectable production.
• Single-use water handling systems.
• Monitoring technologies for microbial and endotoxin control.
• Supply agreements with contract manufacturing organizations.
• Reduced-variability water systems for small-batch specialty injectables.

Pharmaceutical-grade hydrochloric acid

Hydrochloric acid is a commodity excipient in many sterile products, but injectable applications impose tighter requirements than industrial use. Suppliers can differentiate through:

• Trace-metal control.
• Low particulate burden.
• Certificate-of-analysis detail.
• Consistent normality.
• Container compatibility.
• Lot-to-lot documentation.
• Supply security for small-volume sterile manufacturers.

The opportunity is strongest when the supplier provides a qualified sterile or aseptically handled material package, not merely bulk acid.

Oxygen-control technologies

Cysteine’s thiol chemistry creates an opportunity for oxygen management. Potential technologies include:

• Low-oxygen vial headspace.
• Nitrogen or inert-gas overlay.
• Low-permeability elastomers.
• Improved stopper and seal systems.
• Oxygen-scavenging secondary packaging, where compatible with regulatory requirements.
• Container selection that reduces oxygen ingress without creating extractables concerns.

These approaches may support shelf-life extension or reduce degradation, but they also create new extractables, leachables, container closure, and process-validation obligations.

Trace-metal control

Trace metals can catalyze oxidation in amino-acid and cysteine-containing products. Excipient suppliers can offer low-metal grades of water, acids, and other parenteral nutrition components. Manufacturers may also consider process controls that reduce metal contamination from stainless-steel equipment, transfer lines, filters, and filling components.

The commercial value is strongest where trace-metal specifications are linked to demonstrated cysteine stability rather than offered as a generic quality claim.

What formulations could compete with Elcys?

Several formulation concepts could compete with the current vial-based product.

Ready-to-use cysteine-containing parenteral nutrition

A manufacturer could supply premixed amino acid solutions containing cysteine. This would reduce pharmacy manipulation but introduce a larger stability challenge because the product would contain multiple amino acids, electrolytes, and potentially other nutrients.

The principal barriers are:

• Long-term stability of cysteine in the complete matrix.
• Compatibility with calcium and phosphate.
• Sterility and container integrity.
• Shorter beyond-use periods after compounding.
• Greater cold-chain and inventory complexity.
• More difficult dose customization for neonates.

A ready-to-use product could gain adoption if it reduces compounding labor and medication-error risk without creating excessive wastage.

Premeasured additive systems

A prefilled syringe, unit-dose cartridge, or pharmacy-ready transfer device could preserve the flexibility of a separate cysteine additive while reducing vial handling. Such a product would require compatibility data with automated compounding systems, syringe materials, transfer devices, and nutrition bags.

Potential value drivers include:

• Lower manipulation burden.
• Reduced dosing errors.
• Improved traceability.
• Faster preparation in neonatal intensive-care units.
• Integration with automated parenteral nutrition compounding.

The regulatory pathway would depend on whether the device is merely a container-closure presentation or a combination product with a delivery function.

Modified-concentration cysteine products

Alternative concentrations could target high-volume pediatric nutrition programs or reduce storage and shipping requirements. A higher concentration would reduce additive volume but could increase pH, osmolality, precipitation, and local compatibility concerns. A lower concentration could simplify dosing but increase the amount added to the final nutrition solution.

Any concentration change would need comparative data covering stability, dosing accuracy, dilution, and compatibility with common parenteral nutrition formulations.

What manufacturing and IP barriers protect Elcys?

Elcys has a relatively simple composition, so manufacturing barriers are more important than conventional formulation-patent barriers. The strongest defensible assets are likely to be process know-how, analytical methods, stability data, container-closure selection, and regulatory documentation.

Manufacturing barriers

Key barriers include:

1. Sterile production of an acidic amino-acid solution.
2. Control of cysteine oxidation and cystine formation.
3. Low-endotoxin processing.
4. Aseptic filling into single-dose vials.
5. Container closure integrity.
6. Control of visible and subvisible particulates.
7. Validated hold times for bulk solution.
8. Compatibility with parenteral nutrition admixtures.
9. Reliable supply of pharmaceutical-grade WFI and hydrochloric acid.
10. Consistent release testing for assay, pH, impurities, sterility, and endotoxins.

A competing manufacturer can reproduce the listed excipient composition, but it must independently validate the process and demonstrate product quality under FDA requirements for sterile drug products.

Patent and exclusivity position

The public commercial opportunity appears to be governed primarily by regulatory approval, manufacturing capability, and market access rather than by a widely recognized composition-of-matter patent. The FDA Orange Book should be checked for current patent and exclusivity entries associated with NDA 209570 because listings and status can change [2].

IP or regulatory asset	Likely relevance to Elcys
Composition patent	Limited value where the formulation uses cysteine hydrochloride, WFI, and hydrochloric acid
Formulation patent	Could protect defined pH, impurity limits, oxygen control, or stability attributes if granted
Manufacturing patent	Could protect oxidation-control, sterile-processing, or filling methods
Method-of-use patent	Potentially relevant to specific neonatal or pediatric nutrition regimens
Regulatory exclusivity	Must be confirmed in current FDA records
Trade secrets	Likely important for process parameters, stability controls, and analytical methods
Orange Book listing	Must be verified in the current Orange Book

A generic applicant would generally assess whether an abbreviated new drug application is available, whether the reference product is listed in the Orange Book, and whether any listed patents require a Paragraph IV certification. A Paragraph IV challenge could create litigation risk if a listed patent covers the formulation, manufacturing process, or approved use. If no relevant listed patent exists, the commercial barrier shifts toward product development, FDA review, manufacturing scale, and hospital contracting.

When does Elcys lose exclusivity?

Elcys does not have a meaningful exclusivity date that can be stated without confirming the current FDA Orange Book and Drugs@FDA records. The product received FDA approval in 2019, but approval date alone does not establish the end of all regulatory protection.

Relevant dates include:

Milestone	Date or status
FDA approval	2019, NDA 209570
New chemical entity exclusivity	Not assumed; cysteine hydrochloride is an established active ingredient
Orphan-drug exclusivity	Not assumed without an FDA orphan designation
Pediatric exclusivity	Not assumed without a qualifying FDA grant
Listed patent expiration	Must be confirmed in the current Orange Book
Generic entry date	Depends on ANDA filing, review, patent certifications, and approval

FDA approval does not prevent an ANDA applicant from entering automatically after a fixed date unless statutory exclusivity or enforceable patent rights apply. For Elcys, the absence or presence of Orange Book listings is therefore commercially important.

What is the FDA and Orange Book status of Elcys?

Elcys is an FDA-approved cysteine hydrochloride injection product under NDA 209570. The label establishes its concentration, route, use in parenteral nutrition, storage requirements, warnings, and inactive ingredients [1].

The Orange Book is the controlling public source for listed patents, exclusivity codes, therapeutic-equivalence information, and reference-product status [2]. A current diligence review should distinguish among:

• The approved NDA.
• Any current patent listings.
• Any expired or delisted patents.
• Exclusivity codes.
• Authorized generic activity.
• ANDA approvals for therapeutically equivalent cysteine products.
• Product marketing status.

No conclusion about generic launch timing should rely solely on the product label. FDA’s Orange Book and Drugs@FDA records control the relevant regulatory analysis.

Which companies could challenge or compete with Elcys?

Competition can come from four groups:

Generic injectable manufacturers

Established sterile-injectable companies may develop a cysteine hydrochloride injection with the same strength and route. Their advantages include existing vial lines, hospital contracts, and injectable regulatory infrastructure.

Parenteral nutrition manufacturers

Companies that already sell neonatal amino acid solutions or compounded nutrition products could integrate cysteine into broader nutrition offerings. They may compete through bundled purchasing, nutrition-service contracts, and ready-to-use products.

Contract manufacturers

A contract development and manufacturing organization with validated low-oxygen filling and sterile liquid capabilities could support a private-label or authorized-generic strategy.

Compounding pharmacies and outsourcing facilities

Hospital pharmacies and outsourcing facilities may prepare cysteine-containing nutrition solutions under applicable federal and state requirements. These products may compete with a commercial vial where local preparation capacity, shortages, or purchasing economics favor compounding.

The commercial risk from compounding depends on state law, facility accreditation, product availability, hospital policies, and whether the compounded preparation is treated as a patient-specific medication or an outsourcing-facility product.

What generic entry risks exist for Elcys?

Generic entry risk is moderate from a technical perspective and potentially high if no enforceable patent or regulatory exclusivity blocks approval.

A competing product must address:

• Same active ingredient and concentration.
• Injectable quality attributes.
• Sterility and endotoxin control.
• Stability and impurity profile.
• Container closure compatibility.
• Labeling and dilution instructions.
• Bioequivalence or other applicable ANDA requirements.
• Demonstrated pharmaceutical equivalence.

The product is technically easier to copy than a complex biologic or extended-release formulation. Its commercial niche, however, may limit the number of viable entrants because neonatal injectable markets require reliable supply, low defect rates, and specialized hospital access.

A first generic entrant may gain pricing leverage if it can offer dependable supply. Later entrants may face limited volume, lower margins, and hospital contracts that favor established vendors.

How strong is the Elcys patent estate?

The patent estate should be characterized as potentially narrower than the manufacturing and regulatory moat. A simple formulation with two listed inactive ingredients offers limited room for broad composition claims. Stronger patent positions, if they exist, would more likely involve:

• Defined cysteine impurity limits.
• Oxygen-controlled packaging.
• Specific pH ranges tied to stability.
• Manufacturing conditions that limit cystine formation.
• Compatibility with selected parenteral nutrition solutions.
• Specific neonatal dosing or nutrition methods.
• Device-assisted delivery or prefilled presentations.

The commercial strength of any such patent would depend on claim scope, written-description support, enforceability, Orange Book listing, and the ability to prove infringement from publicly observable product characteristics.

What licensing and partnership opportunities exist?

The most attractive licensing opportunities are adjacent to the drug product rather than centered on the basic cysteine hydrochloride molecule.

Potential deal structures include:

• Licensing a ready-to-use cysteine-containing parenteral nutrition formulation.
• Supplying qualified low-metal WFI or hydrochloric acid.
• Licensing oxygen-control packaging.
• Co-developing a prefilled syringe or transfer-device presentation.
• Contract manufacturing with dedicated neonatal injectable capacity.
• Hospital-system partnerships focused on automated parenteral nutrition compounding.
• Distribution agreements with pediatric and neonatal specialty suppliers.

A formulation license becomes more valuable if it provides demonstrable stability, reduced preparation time, or lower medication-error risk. A raw-material supply agreement becomes more defensible when the supplier has validated specifications and change-control systems accepted by the finished-dose manufacturer.

How does Elcys compare with alternative cysteine supply models?

Model	Main advantage	Main limitation	Commercial opportunity
Elcys vial additive	Flexible dosing and established use	Requires pharmacy manipulation	Baseline reference product
Generic vial	Potentially lower price	Must establish supply reliability	Price competition
Ready-to-use amino acid solution with cysteine	Reduced compounding	Complex stability and inventory	Premium workflow product
Prefilled syringe or cartridge	Dose and handling convenience	Device compatibility and cost	NICU workflow differentiation
Pharmacy-compounded cysteine	Local flexibility	Quality, labor, and regulatory burden	Substitution during supply constraints
Automated compounding integration	Reduces manual steps	Capital and software integration	Hospital-system contracting

What are the main revenue and market-access considerations?

Elcys is a specialized hospital product, so revenue exposure depends more on unit availability and formulary position than on mass-market prescribing. Demand is concentrated in neonatal intensive-care units, pediatric hospitals, parenteral nutrition programs, and institutions that manage high-acuity patients.

Commercial variables include:

• Number of neonatal intensive-care beds.
• Frequency of parenteral nutrition use.
• Cysteine supplementation protocols.
• Hospital purchasing contracts.
• Product shortages or back orders.
• Wastage from single-dose packaging.
• Pharmacy labor costs.
• Reimbursement treatment of compounded nutrition.
• Availability of substitute cysteine products.
• Distributor inventory and service levels.

A differentiated presentation can support a premium if it reduces compounding time, limits dosing errors, improves traceability, or reduces wastage. A basic generic vial is more likely to compete on price and supply continuity.

Key Takeaways

• Elcys uses a minimal excipient system: Water for Injection and hydrochloric acid.
• The main formulation risks are cysteine oxidation, cystine formation, pH control, trace metals, oxygen exposure, and admixture compatibility.
• Commercial opportunities are strongest in low-endotoxin excipients, low-metal raw materials, oxygen-control packaging, prefilled delivery systems, and ready-to-use parenteral nutrition.
• Manufacturing and regulatory execution may provide a stronger barrier than broad formulation patent coverage.
• Generic entry depends on current Orange Book listings, regulatory exclusivity, ANDA requirements, and the ability to manufacture a reliable sterile injectable.
• A ready-to-use or device-assisted presentation could compete through pharmacy-workflow benefits rather than active-ingredient differentiation.
• The relevant market is specialized and hospital-driven, with commercial value concentrated in neonatal and pediatric parenteral nutrition.

FAQs

Is hydrochloric acid an active ingredient in Elcys?

No. Cysteine hydrochloride is the active drug substance. Hydrochloric acid is listed as an inactive ingredient used for pH adjustment.

Does Elcys contain benzyl alcohol or other preservatives?

The FDA label identifies Elcys as preservative-free. Hydrochloric acid and Water for Injection are listed as inactive ingredients [1].

Can Elcys be sold as a premixed parenteral nutrition product?

A premixed product would require its own formulation, stability, compatibility, container, labeling, and FDA regulatory strategy. It would not automatically be covered by the approval of the vial product.

Could an excipient patent block a generic cysteine injection?

Yes, if an enforceable patent claims a formulation, container system, manufacturing method, or approved use and is listed or otherwise relevant to the generic applicant’s certification strategy. The current Orange Book must be reviewed for listed patents [2].

Is Elcys a biologic with biosimilar competition?

No. Elcys is a small-molecule sterile injectable. Competition would generally involve generic or alternative drug applications, not biosimilar pathways.

References

1. U.S. Food and Drug Administration. (2019). Elcys (cysteine hydrochloride injection) prescribing information. Exela Pharma Sciences, LLC.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary.
5. U.S. Food and Drug Administration. (2004). Sterile drug products produced by aseptic processing: Current good manufacturing practice guidance for industry.